PREGALIN 150
Capsule
Dose Type
Information
PREGALIN 150 is brand name of Pregabalin 150mg.Pregabalin is an anti-epileptic drug and also known as an anti-convulsant drug. Pregabalin works by slowing down impulses in the brain that cause seizures. It also affects chemicals in the brain that send pain signals across the nervous system.
Therapeutic Class
Anticonvulsant
Dose and Direction of Use
For oral administration, it can be taken with or without food. The dosage is based upon your medical condition and response to treatment.
Discontinuation of Pregabalin: In accordance with current clinical practice, if Pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
Mode of Action
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. In vitro, Pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function. It also interacts with the serotonergic and noradrenergic pathways originating from the brain stem and reduce neuropathic pain transmission from spinal cord.
Uses
Neuropathic pain: Pregabalin is indicated for the treatment of peripheral and central neuropathic pain in adults.
Epilepsy: Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Generalised anxiety disorder:Pregabalin is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Controls seizures and treat fibromyalgia. It is also used to treat pain caused by nerve damage in people with diabetes (diabetic neuropathy), herpes zoster (post-herpetic neuralgia, or neuropathic pain associated with spinal cord injury.
Contraindications
Don't use this medicine if you have:
- Hypersensitivity to this medicine
Precautions and Warning
- Some diabetic patients who gain weight on Pregabalin treatment may need to adjust hypoglycemic medications.
- Hypersensitivity reactions, including cases of angioedema have been reported after the use of Pregabalin. Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.
- Visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient. Discontinuation of Pregabalin may result in resolution or improvement of these visual symptoms.
- Convulsions, including status epilepticus and grand mal convulsions, may occur during Pregabalin use or shortly after discontinuing Pregabalin.
- Congestive heart failure in some patients receiving Pregabalin has been reported, mostly in elderly cardiovascular compromised patients during treatment for a neuropathic indication. Discontinuation of Pregabalin may resolve the reaction.
- Patients with a history of substance abuse should be monitored for symptoms of Pregabalin abuse.
- Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.
- Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury in elderly population. Cases of loss of consciousness, confusion and mental impairment have also been reported. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication.
- There are insufficient data for the withdrawal of concomitant antiepileptic medical products, once seizure control with Pregabalin in the add-on situation has been reached, in order to reach monotherapy on Pregabalin.
- After discontinuation of short-term and long-term treatment with Pregabalin withdrawal symptoms have been observed in some patients, (e.g. insomnia, headache, nausea, diarrhoea, flu syndrome, nervousness, depression, pain, sweating and dizziness). The patient should be informed about this at the start of the treatment. Concerning discontinuation of long-term treatment of Pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose related.
- In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse events in general, central nervous system adverse events and especially somnolence was increased. This may be attributed to an additive effect due to concomitant medication (e.g. anti-spasticity agents) needed for this condition.
- Cases of renal failure have been reported. Some cases were reversible upon discontinuation of treatment.
- Patients should be monitored for signs of suicidal ideation and behaviors. Appropriate treatment should be considered.
- When Pregabalin and opioids are co-administered, measures to prevent constipation may be considered (especially in female patients and elderly).
